Page 414 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(11) Light D, editor. The Risks of Prescription Drugs (A Columbia/SSRC
Book. Columbia University Press; 2010).

(12) Survey of FDA Scientists Shows They Feel Pressure to Ex-
clude …: Oncology Times [Internet]. [cited 2012 May 6]. Available
from: http://journals.lww.com/oncology-times/Fulltext/2006/08250/
Survey_of_FDA_Scientists_Shows_T hey_Feel_Pressure.8.aspx.

(13) USATODAY.com—Survey: FDA scientists question safety [Inter-
net]. [cited 2012 May 6]. Available from: http://www.usatoday.com/news/
health/2004-12-16-fda-survey-usat_x.htm.

(14) European Journal of Clinical Pharmacology 2011 10.1007/s00
228-011-1052-1 Anything new in EU pharmacovigilance? Silvio Garattini
and Vittorio Bertele’.

(15) Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of
Comparative Efficacy Data at the Time of Drug Approval in the United
States. JAMA: The Journal of the American Medical Association. 2011 May
4;305(17):1786–9.

(16) Bertele’ V, Banzi R, Gluud C, Garattini S. EMA’s reflection on
placebo does not reflect patients’ interests. European Journal of Clin-
ical Pharmacology [Internet]. 2011 Dec 2 [cited 2012 Feb 13]; Epub
ahead of print. Available from: http://www.springerlink.com/content/
4j733734v35381jk/.

(17) Garattini S, Chalmers I. Patients and the public deserve big
changes in evaluation of drugs. BMJ. 2009 Mar 31;338(mar31 3):b1025-
b1025.

(18) Van Luijn JCF, Gribnau FWJ, Leufkens HGM. Availability of
comparative trials for the assessment of new medicines in the Euro-
pean Union at the moment of market authorization. Br J Clin Pharmacol.
2007;63(2):159–162.

414